Takeda has announced the official launch of its Innovation Capability location (ICC) in Bengaluru, India. As part of its worldwide digital transformation, which includes insourcing capabilities, digital solutions will be developed at this location. After successful openings in Slovakia and Mexico, this is Takeda’s first ICC in Asia. The company’s commitment to improving healthcare through creative solutions is supported by the ICC. For years to come, Takeda’s employees, the patients we serve, and the environment will all be impacted by these innovative solutions that will help us improve our operations.
Takeda’s strategic commitment to using data and emerging digital technologies, such artificial intelligence, to speed up research and development with the ultimate objective of improving patient outcomes is reflected in the introduction of ICC India. With a strong dedication to its basic values—integrity, fairness, honesty, and perseverance—Takeda is committed to improving people’s health and the future of the globe. With a long history that began in Osaka, Japan, in 1781, Takeda has developed into a major player in the biopharmaceutical industry with operations in almost 80 countries, including India for more than 13 years. With the support of strategic alliances, the company’s goal in India is to provide long-term access to healthcare. Takeda’s broad range of medicines covers immunology, cancer, rare illnesses, gastrointestinal disorders, and vaccines, demonstrating its dedication to data-driven innovation and game-changing medical care.
The creation of this competence center demonstrates Takeda’s goal to become one of the most reputable, morally grounded, R&D-focused biopharmaceutical businesses, utilizing Karnataka’s thriving innovation ecosystem to meet patient demands.
“The launch of our Bengaluru ICC is a pivotal moment for Takeda’s digital transformation journey,” said Gabriele Ricci, Chief Data and Technology Officer at Takeda. “Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve. Investing in India’s remarkable talent and technological expertise underscores Takeda’s commitment leveraging local expertise to deliver innovative, data-driven solutions and sustainable growth.”
By embracing data and digital solutions with an agile, patient-centric, and solution-focused approach, the ICC in India will build critical technological skills to spur innovation. The ICC will focus on cutting-edge developments in a variety of fields, such as:
Using GenAI and Artificial Intelligence (AI) to improve healthcare’s predictive analytics and efficiency
Using application virtualization and device engineering to promote innovation in product development and patient-centered solutions
Data-driven decision-making for better patient outcomes is made possible by data science and visualization.
“India was a natural choice for Takeda’s first ICC in Asia,” said Tilak Banerjee, Head of Takeda ICC India. “This strategic commitment will generate new jobs and further the company’s global mission of delivering life-transforming treatments to patients.”
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter
About us:
The Mainstream formerly known as CIO News is the premier platform dedicated to delivering the latest news, updates, and insights from the CIO industry. As a trusted source in the technology and IT sector, we provide a comprehensive resource for executives and professionals seeking to stay informed and ahead of the curve. With a focus on cutting-edge developments and trends, The Mainstream formerly known as CIO News serves as your go-to destination for staying abreast of the rapidly evolving landscape of technology and IT. Founded in June 2020, The Mainstream formerly known as CIO News has rapidly evolved with ambitious growth plans to expand globally, targeting markets in the Middle East & Africa, ASEAN, USA, and the UK
